ResearcherHarvard UniversityActive in the last 2 years
Sarah Slater
Matched on ORCID iD 0009-0004-0683-5436; OpenAlex author ID A5018367841, A5109953560. Sources: ClinicalTrials.gov.
Their work
- Papers
- 5
- Trials
- 1 (principal investigator on 1)
- Grants
- 0
- Labs led
- 0
- Collaborators
- 57
2016: 1 trial · 2017: none · 2018: none · 2019: none · 2020: 1 paper · 2021: none · 2022: none · 2023: none · 2024: none · 2025: 1 paper · 2026: 3 papers
Papers 5
- Dendritic cell redundancy enables priming of anti-tumor CD4+ T cells in pancreatic cancer. Co-author DOI 10.1016/j.ccell.2026.04.005↗
- CD4 T cells convert transient responses to KRAS inhibition to durable remissions in pancreatic cancer. Co-author DOI 10.1016/j.cell.2026.08.045↗
- Immune and stromal features of durable complete response to radiation and dual immune checkpoint blockade in pancreatic cancer Co-author DOI 10.64898/2026.08.06.26359422↗
- Open-Label, Phase II Trial of Extracellular Regulated Kinase Inhibition Alone and in Combination With Autophagy Inhibition in Patients With Metastatic Pancreat… Co-author DOI 10.1200/po-25-00332↗
- Phase I clinical trial repurposing all-trans retinoic acid as a stromal targeting agent for pancreatic cancer. Co-author DOI 10.1038/s41467-020-18636-w↗
Trials 1
- Stromal TARgeting for PAncreatic Cancer (STAR_PAC) Principal investigator NCT03307148↗
Closest collaborators
The 25 strongest of 57 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.
- Brian Matthew Wolpin · 4 shared papers, 2025–2026 · strength 0.72
- Paper Dendritic cell redundancy enables priming of anti-tumor CD4+ T cells in pancreatic cancer. DOI 10.1016/j.ccell.2026.04.005↗
- Paper CD4 T cells convert transient responses to KRAS inhibition to durable remissions in pancreatic cancer. DOI 10.1016/j.cell.2026.08.045↗
- Paper Immune and stromal features of durable complete response to radiation and dual immune checkpoint blockade in pancreatic… DOI 10.64898/2026.08.06.26359422↗
- Joseph Douglas Mancias · 4 shared papers, 2025–2026 · strength 0.72
- Paper Dendritic cell redundancy enables priming of anti-tumor CD4+ T cells in pancreatic cancer. DOI 10.1016/j.ccell.2026.04.005↗
- Paper CD4 T cells convert transient responses to KRAS inhibition to durable remissions in pancreatic cancer. DOI 10.1016/j.cell.2026.08.045↗
- Paper Immune and stromal features of durable complete response to radiation and dual immune checkpoint blockade in pancreatic… DOI 10.64898/2026.08.06.26359422↗
- James M. Cleary · 4 shared papers, 2025–2026 · strength 0.72
- Paper Dendritic cell redundancy enables priming of anti-tumor CD4+ T cells in pancreatic cancer. DOI 10.1016/j.ccell.2026.04.005↗
- Paper CD4 T cells convert transient responses to KRAS inhibition to durable remissions in pancreatic cancer. DOI 10.1016/j.cell.2026.08.045↗
- Paper Immune and stromal features of durable complete response to radiation and dual immune checkpoint blockade in pancreatic… DOI 10.64898/2026.08.06.26359422↗
- Harshabad Singh · 3 shared papers, 2025–2026 · strength 0.53
- Paper Dendritic cell redundancy enables priming of anti-tumor CD4+ T cells in pancreatic cancer. DOI 10.1016/j.ccell.2026.04.005↗
- Paper CD4 T cells convert transient responses to KRAS inhibition to durable remissions in pancreatic cancer. DOI 10.1016/j.cell.2026.08.045↗
- Paper Open-Label, Phase II Trial of Extracellular Regulated Kinase Inhibition Alone and in Combination With Autophagy Inhibit… DOI 10.1200/po-25-00332↗
- Douglas Adam Rubinson · 3 shared papers, 2025–2026 · strength 0.53
- Paper Dendritic cell redundancy enables priming of anti-tumor CD4+ T cells in pancreatic cancer. DOI 10.1016/j.ccell.2026.04.005↗
- Paper CD4 T cells convert transient responses to KRAS inhibition to durable remissions in pancreatic cancer. DOI 10.1016/j.cell.2026.08.045↗
- Paper Open-Label, Phase II Trial of Extracellular Regulated Kinase Inhibition Alone and in Combination With Autophagy Inhibit… DOI 10.1200/po-25-00332↗
- Brandon M. Huffman · 3 shared papers, 2025–2026 · strength 0.53
- Paper Dendritic cell redundancy enables priming of anti-tumor CD4+ T cells in pancreatic cancer. DOI 10.1016/j.ccell.2026.04.005↗
- Paper CD4 T cells convert transient responses to KRAS inhibition to durable remissions in pancreatic cancer. DOI 10.1016/j.cell.2026.08.045↗
- Paper Open-Label, Phase II Trial of Extracellular Regulated Kinase Inhibition Alone and in Combination With Autophagy Inhibit… DOI 10.1200/po-25-00332↗
- Jonathan Andrew Nowak · 3 shared papers, 2025–2026 · strength 0.53
- Paper Dendritic cell redundancy enables priming of anti-tumor CD4+ T cells in pancreatic cancer. DOI 10.1016/j.ccell.2026.04.005↗
- Paper CD4 T cells convert transient responses to KRAS inhibition to durable remissions in pancreatic cancer. DOI 10.1016/j.cell.2026.08.045↗
- Paper Open-Label, Phase II Trial of Extracellular Regulated Kinase Inhibition Alone and in Combination With Autophagy Inhibit… DOI 10.1200/po-25-00332↗
- Kimberly J. Perez · 3 shared papers, 2025–2026 · strength 0.53
- Paper Dendritic cell redundancy enables priming of anti-tumor CD4+ T cells in pancreatic cancer. DOI 10.1016/j.ccell.2026.04.005↗
- Paper CD4 T cells convert transient responses to KRAS inhibition to durable remissions in pancreatic cancer. DOI 10.1016/j.cell.2026.08.045↗
- Paper Open-Label, Phase II Trial of Extracellular Regulated Kinase Inhibition Alone and in Combination With Autophagy Inhibit… DOI 10.1200/po-25-00332↗
- Michael Lawrence Dougan · 2 shared papers, 2026 · strength 0.38
- Courtney T.S. Kureshi · 2 shared papers, 2026 · strength 0.38
- Chong Zuo · 2 shared papers, 2026 · strength 0.38
- George Molina · 2 shared papers, 2026 · strength 0.38
- Thomas E. Clancy · 2 shared papers, 2026 · strength 0.38
- Stephanie K. Dougan · 2 shared papers, 2026 · strength 0.38
- Andrew J. Aguirre · 2 shared papers, 2025–2026 · strength 0.34
- Thomas Adam Abrams · 2 shared papers, 2025–2026 · strength 0.34
- Paper Immune and stromal features of durable complete response to radiation and dual immune checkpoint blockade in pancreatic… DOI 10.64898/2026.08.06.26359422↗
- Paper Open-Label, Phase II Trial of Extracellular Regulated Kinase Inhibition Alone and in Combination With Autophagy Inhibit… DOI 10.1200/po-25-00332↗
- Matthew B.B. Yurgelun · 2 shared papers, 2025–2026 · strength 0.34
- Paper Immune and stromal features of durable complete response to radiation and dual immune checkpoint blockade in pancreatic… DOI 10.64898/2026.08.06.26359422↗
- Paper Open-Label, Phase II Trial of Extracellular Regulated Kinase Inhibition Alone and in Combination With Autophagy Inhibit… DOI 10.1200/po-25-00332↗
- Aparna R. Parikh · 2 shared papers, 2025–2026 · strength 0.34
- Paper Immune and stromal features of durable complete response to radiation and dual immune checkpoint blockade in pancreatic… DOI 10.64898/2026.08.06.26359422↗
- Paper Open-Label, Phase II Trial of Extracellular Regulated Kinase Inhibition Alone and in Combination With Autophagy Inhibit… DOI 10.1200/po-25-00332↗
- Colin D. Weekes · 2 shared papers, 2025–2026 · strength 0.34
- Paper Immune and stromal features of durable complete response to radiation and dual immune checkpoint blockade in pancreatic… DOI 10.64898/2026.08.06.26359422↗
- Paper Open-Label, Phase II Trial of Extracellular Regulated Kinase Inhibition Alone and in Combination With Autophagy Inhibit… DOI 10.1200/po-25-00332↗
- Hemant Mahendrakumar Kocher · 1 shared paper, 1 shared trial, 2016–2020 · strength 0.27
- Victoire Cardot‐Ruffino · 1 shared paper, 2026 · strength 0.19
- Lestat R. Ali · 1 shared paper, 2026 · strength 0.19
- Qiang Li · 1 shared paper, 2026 · strength 0.19
- Megan T. Hoffman · 1 shared paper, 2026 · strength 0.19
- Brendan D. Parent · 1 shared paper, 2026 · strength 0.19
How to reach this person
A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.